G. Masters

发表

Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.

M. Gilbert, M. Kris, E. Basch, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.

W. Curran, K. Forster, P. Iyengar, 2015, The Lancet. Oncology.

Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non–Small Cell Lung Cancer: A Phase I Dose Escalation Study

T. De Pas, J. Pujol, M. Debois, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase I study of vinorelbine and ifosfamide in advanced non-small-cell lung cancer.

E. Vokes, R. Mick, G. Masters, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update Summary.

N. Hanna, S. Temin, G. Masters, 2020, JCO oncology practice.

Precision Medicine in Lung Cancer Treatment.

G. Masters, D. Shah, 2020, Surgical oncology clinics of North America.

Screening for lung cancer--a review.

G. Masters, D. Ray, T. Kuźniar, 2004, Medical science monitor : international medical journal of experimental and clinical research.

Phase I study of docetaxel with concomitant thoracic radiation therapy.

E. Vokes, D. Haraf, G. Masters, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of vinorelbine, cisplatin, and concomitant thoracic radiation in the treatment of advanced chest malignancies.

E. Vokes, D. Haraf, G. Masters, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pemetrexed in Second Line and beyond Small Cell Lung Cancer: A Hoosier Oncology Group Phase II Study

N. Hanna, R. Govindan, Menggang Yu, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase I/II trial of induction chemotherapy with carboplatin and gemcitabine followed by concurrent vinorelbine and paclitaxel with chest radiation in patients with stage III non-small cell lung cancer.

A. Argiris, M. Liptay, M. Kies, 2004, Lung cancer.

Gemcitabine and carboplatin in advanced non small-cell lung cancer: a review.

G. Masters, 2000, Clinical lung cancer.

A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer.

M. Ratain, E. Vokes, G. Masters, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Intraoperative sentinel lymph node mapping in non-small-cell lung cancer improves detection of micrometastases.

W. Fry, M. Liptay, S. Grondin, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sacituzumab Govitecan, a Trop-2-Directed Antibody-Drug Conjugate, for Patients with Epithelial Cancer: Final Safety and Efficacy Results from the Phase 1/2 IMMU-132-01 Basket Trial.

J. Berlin, A. Bardia, J. Lang, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Relationship between symptom change, objective tumor measurements, and performance status during chemotherapy for advanced lung cancer.

B. Parasuraman, D. Cella, D. Eton, 2008, Clinical lung cancer.

Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105.

M. Socinski, E. Vokes, J. Rosenman, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study.

C. Rudin, E. Vokes, D. Huo, 2002, Lung cancer.

Fatty acid transporter 2 reprograms neutrophils in cancer

N. Hockstein, Fang Wang, E. Ricciotti, 2019, Nature.

Phase II study of carboplatin, pemetrexed, and bevacizumab in advanced nonsquamous non–small‐cell lung cancer

G. Masters, C. Schneider, M. Guarino, 2018, Cancer medicine.

Case for Stopping Targeted Therapy When Lung Cancer Progresses on Treatment in Hospice-Eligible Patients.

Thomas J. Smith, G. Giaccone, N. Hanna, 2017, Journal of oncology practice.

美国临床肿瘤学会Ⅳ期非小细胞肺癌化疗的临床实践指南更新

Thomas J. Smith, G. Giaccone, C. Azzoli, 2010, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Attention to diet, exercise, and weight in oncology care: Results of an American Society of Clinical Oncology national patient survey

Caroline Schenkel, L. Pierce, J. Ligibel, 2022, Cancer.

Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies: HOG LUN 07-130

N. Hanna, S. Badve, L. Einhorn, 2017, American journal of clinical oncology.

An innovative symptom monitoring tool for people with advanced lung cancer: a pilot demonstration.

D. Cella, D. Eton, S. Yount, 2007, The journal of supportive oncology.

Barriers exist to patient participation in clinical trials

A. Guarino, G. Masters, C. Schneider, 2005 .

A Phase II Study of Topotecan and Cyclophosphamide with G-CSF in Patients with Small Cell Lung Cancer with Poor Prognostic Factors

E. Kraut, K. Blum, G. Masters, 2004 .

A Review of Concurrent Chemo/Radiation, Immunotherapy, Radiation Planning, and Biomarkers for Locally Advanced Non-small Cell Lung Cancer and Their Role in the Development of ECOG-ACRIN EA5181.

C. Lovly, M. Harkenrider, N. Pennell, 2022, Clinical lung cancer.

A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer and the Rationale for the ECOG-ACRIN EA5181 Study

Katz, H. Wakelee, M. Diehn, 2021 .

Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline

Gregory Riely, S. Temin, P. Ellis, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

S. Temin, G. Masters, David H. Johnson, 2016, Journal of oncology practice.

Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.

N. Hanna, Gregory Riely, L. Gaspar, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Case Report of the Clinico-radiologic Challenges of Assessing Treatment Response after Stereotactic Radiation of Oligometastases Preceded by Immunotherapy: Pseudoprogression, Mixed Response Patterns, and Opportunities for Precision Radiation

G. Masters, A. Rashid, S. Venigalla, 2019, Cureus.

Clinical cancer advances 2010: annual report on progress against cancer from the American Society of Clinical Oncology.

M. Kris, L. Newman, N. Petrelli, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Alliance A082002 -a randomized phase II/III trial of modern immunotherapy-based systemic therapy with or without SBRT for PD-L1-negative, advanced non-small cell lung cancer.

Ashutosh Kumar Singh, A. Amini, D. Kozono, 2022, Clinical lung cancer.

Ifosfamide and vinorelbine in advanced non-small cell lung cancer

E. Vokes, G. Masters, B. Samuels, 1997 .

Ifosfamide plus paclitaxel in advanced non-small-cell lung cancer: a phase I study.

E. Vokes, G. Masters, B. Samuels, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Carboplatin and vinorelbine in advanced non-small cell lung cancer: a phase I/II study.

G. Masters, 2001, The oncologist.

Original article A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer

M. Ratain, E. Vokes, G. Masters, 2005 .

A phase I-II study of paclitaxel, ifosfamide, and vinorelbine with filgrastim (rhG-CSF) support in advanced non-small-cell lung cancer.

E. Vokes, G. Masters, B. Samuels, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-Term Results of RTOG 0617: A Randomized Phase 3 Comparison of Standard Dose Versus High Dose Conformal Chemoradiation Therapy +/- Cetuximab for Stage III NSCLC

W. Curran, K. Forster, P. Iyengar, 2017 .

Overview of head and neck cancer.

G. Masters, B. Brockstein, 2003, Cancer treatment and research.

Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597.

C. Blanke, A. Sandler, K. Miller, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CD45 phosphatase regulates the fate of myeloid cells in tumor microenvironment by inhibiting STAT3 activity

N. Hockstein, F. Denstman, H. Du, 2016 .

Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline

Gregory Riely, S. Temin, P. Ellis, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Concomitant radiation therapy and paclitaxel for unresectable locally advanced breast cancer: results from two consecutive phase I/II trials.

J. Kao, S. Conzen, W. Recant, 2005, International journal of radiation oncology, biology, physics.

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

Thomas J. Smith, G. Giaccone, C. Azzoli, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intraoperative radioisotope sentinel lymph node mapping in non-small cell lung cancer.

D. Winchester, W. Fry, M. Liptay, 2000, The Annals of thoracic surgery.

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

S. Temin, G. Masters, David H. Johnson, 2016, Journal of oncology practice / American Society of Clinical Oncology.

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events

P. Ascierto, Rajeev Sharma, J. Sosman, 2021, Journal for ImmunoTherapy of Cancer.

Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients

George A. Dominguez, N. Hockstein, J. Mehta, 2016, Science Immunology.

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary.

N. Hanna, S. Temin, G. Masters, 2017, Journal of oncology practice.

Distinct Populations of Immune-Suppressive Macrophages Differentiate from Monocytic Myeloid-Derived Suppressor Cells in Cancer

N. Hockstein, L. Montaner, A. Kossenkov, 2020, Cell reports.

Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.

N. Hanna, Gregory Riely, L. Gaspar, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analysis of classical neutrophils and polymorphonuclear myeloid-derived suppressor cells in cancer patients and tumor-bearing mice

H. Dweep, S. Singhal, R. Cristescu, 2021, The Journal of experimental medicine.

ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis.

N. Hockstein, W. El-Deiry, E. Celis, 2014, The Journal of clinical investigation.

Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit

Nickolay A. Khazanov, M. Burkard, D. Rhodes, 2023, Communications Medicine.

CD45 Phosphatase Inhibits STAT3 Transcription Factor Activity in Myeloid Cells and Promotes Tumor-Associated Macrophage Differentiation.

N. Hockstein, F. Denstman, H. Du, 2016, Immunity.

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

Thomas J. Smith, Thomas J Smith, Gregory J Riely, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study.

J. Jett, F. Khuri, H. Choy, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quality of Life Analysis of a Radiation Dose-Escalation Study of Patients With Non-Small-Cell Lung Cancer: A Secondary Analysis of the Radiation Therapy Oncology Group 0617 Randomized Clinical Trial.

W. Curran, H. Choy, J. Sloan, 2016, JAMA oncology.

Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance).

E. Vokes, G. Otterson, H. Pang, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer.

Thomas J. Smith, G. Giaccone, C. Azzoli, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapeutic management of stage IV non-small cell lung cancer.

David E Morris, M. Socinski, R. Lilenbaum, 2003, Chest.

New Treatments for Advanced Non-Small-Cell Lung Cancer

G. Masters, 2002 .

Sex-associated differences in survival of patients undergoing resection for lung cancer.

E. Vokes, D. Haraf, G. Masters, 2000, The Annals of thoracic surgery.

Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.

Carl Morrison, S. Jewell, C. Morrison, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quality of life in lung cancer: the validity and cross-cultural applicability of the Functional Assessment Of Cancer Therapy-Lung scale.

J. Beaumont, D. Cella, D. Eton, 2005, Hematology/oncology clinics of North America.

Real-time clinical application of quality-of-life assessment in advanced lung cancer.

D. Cella, A. Peterman, G. Masters, 2002, Clinical lung cancer.

A phase II trial of high dose carboplatin and paclitaxel with G-CSF and peripheral blood stem cell support followed by surgery and/or chest radiation in patients with stage III non-small cell lung cancer: CALGB 9531.

E. Vokes, T. Shea, G. Masters, 2011, Lung cancer.

Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I–inhibiting Antibody–Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan

R. Heist, D. Camidge, W. Messersmith, 2017, Clinical Cancer Research.

Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer.

K. Forster, P. Iyengar, H. Choy, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103.

C. Rudin, R. Salgia, E. Vokes, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical Practice Guideline Update on Chemotherapy for Stage IV Non – Small-Cell Lung Cancer

Thomas J. Smith, G. Giaccone, C. Azzoli, 2009 .

[American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer].

Thomas J. Smith, G. Giaccone, C. Azzoli, 2010, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

A Phase II Trial of Carboplatin and Gemcitabine with Exisulind (IND #65,056) in Patients with Advanced Non-small Cell Lung Cancer: An Eastern Cooperative Oncology Group Study (E1501)

Sigui Li, J. Schiller, C. Langer, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The validity and clinical utility of symptom monitoring in advanced lung cancer: a literature review.

D. Cella, G. Masters, S. Burch, 2002, Clinical lung cancer.

Commentary on “Pilot and Safety Trial of Carboplatin, Paclitaxel, and Thalidomide in Advanced Non–Small-Cell Lung Cancer”

G. Masters, 2000 .

Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer.

J. Hainsworth, J. Hamm, K. Albain, 2011, Lung cancer.

A randomized, double‐blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive‐stage small cell lung cancer: Hoosier Cancer Research Network LUN06‐113

N. Hanna, J. Patel, G. Masters, 2017, Cancer.

Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology.

Richard L Schilsky, Michael N Neuss, Howard A Fine, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fatty acid transporter 2 reprograms neutrophils in cancer

N. Hockstein, E. Ricciotti, P. Lieberman, 2019, Nature.

A review of immunotherapy for stage 3 and metastatic NSCLC & the rationale for the ECOG-ACRIN EA5181 study.

Sharyn I. Katz, D. Mankoff, H. Wakelee, 2021, The oncologist.

Epithelioid inflammatory myofibroblastic sarcoma: a case report.

Jessica A. Clevenger, T. Bauer, G. Masters, 2015, Journal of thoracic disease.

Clinical Presentation of Lung Cancer

G. Masters, K. Oh, 2004 .

Multimodality approach to management of stage III non-small cell lung cancer.

D. Jarrar, G. Masters, P. Mitra, 2013, Surgical oncology clinics of North America.

Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan.

J. Berlin, A. Bardia, R. Heist, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trop-2 as a therapeutic target for the antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132), in patients (pts) with previously treated metastatic small-cell lung cancer (mSCLC).

A. Bardia, R. Heist, D. Camidge, 2016 .

Institutional Enrollment and Survival Among NSCLC Patients Receiving Chemoradiation: NRG Oncology Radiation Therapy Oncology Group (RTOG) 0617.

W. Curran, J. Bradley, C. Robinson, 2016, Journal of the National Cancer Institute.

Progress in lung cancer: ASCO 2015.

G. Masters, 2015, Surgical oncology.

Immune suppressive activity of myeloid-derived suppressor cells in cancer requires inactivation of the type I interferon pathway

A. Rynda-Apple, N. Hockstein, Joseph Bennett, 2021, Nature Communications.

Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas.

K. Takakura, L. Lunsford, P. Black, 1997, Neurosurgery.

Identification of monocyte-like precursors of granulocytes in cancer as a mechanism for accumulation of PMN-MDSCs

George A. Dominguez, Joseph Bennett, L. Languino, 2019, The Journal of experimental medicine.

Phase I dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors

M. Ratain, S. Mani, G. Masters, 2003 .

Clinical Oncology, Second Edition

J. Niederhuber, G. Masters, M. Abeloff, 2000 .

Unique pattern of neutrophil migration and function during tumor progression

George A. Dominguez, N. Hockstein, L. Languino, 2018, Nature Immunology.

A Phase II Study of Induction Chemotherapy Followed by Thoracic Radiotherapy and Erlotinib in Poor-Risk Stage III Non–Small-Cell Lung Cancer: Results of CALGB 30605 (Alliance)/RTOG 0972 (NRG)

P. Jänne, J. Bradley, E. Vokes, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy with or without cetuximab for stage III non-small cell lung cancer: Results on radiation dose in RTOG 0617.

W. Curran, K. Forster, H. Choy, 2013 .

Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.

Susan M. Chang, Nicholas J Vogelzang, J. V. Von Roenn, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II Study of Vinorelbine and Exisulind as First-Line Treatment of Advanced Non-small Cell Lung Cancer in Patients at Least 70 Years Old: A Wisconsin Oncology Network Study

KyungMann Kim, J. Schiller, G. Masters, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538

J. Bradley, R. Komaki, L. Gaspar, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Unique pattern of neutrophil migration and function during tumor progression

George A. Dominguez, N. Hockstein, L. Languino, 2018, Nature Immunology.

Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.

Susanne M Arnold, Mary W Redman, Karen Kelly, 2018, The Lancet. Oncology.

A Randomized Phase II Trial Using Two Different Treatment Schedules of Gemcitabine and Carboplatin in Patients with Advanced Non–Small-Cell Lung Cancer

L. Bloss, C. Obasaju, E. Hahn, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Paclitaxel/carboplatin plus ifosfamide in non-small cell lung cancer.

E. Vokes, G. Masters, H. Golomb, 1997, Seminars in oncology.

Phase II trial of gemcitabine in patients with previously untreated metastatic cancer of the esophagus or gastroesophageal junction.

L. Einhorn, E. Mitchell, H. Kindler, 2000, Annals of Oncology.

A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinb in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19.

J. Jett, M. Tsao, K. Ding, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Topotecan therapy in patients with relapsed small-cell lung cancer and poor performance status.

R. Huber, R. Lilenbaum, G. Masters, 2006, Clinical lung cancer.

Combined Analysis of Molecular and Clinical Predictors of Gefitinib Activity in Advanced Non–Small Cell Lung Cancer: Epidermal Growth Factor Receptor Mutations Do Not Tell the Whole Story

T. Hensing, J. Kolesar, A. Argiris, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Should non-small cell carcinoma of the lung be treated with chemotherapy? Pro: chemotherapy is for non-small cell lung cancer.

E. Vokes, G. Masters, 1995, American journal of respiratory and critical care medicine.

Phase I/II trial of vinorelbine and divided-dose carboplatin in advanced non-small cell lung cancer.

E. Hahn, M. Kies, G. Masters, 2003, Lung cancer.

Randomized phase III Trial of MEDI4736 (durvalumab) as concurrent and consolidative therapy or consolidative therapy alone for unresectable stage 3 NSCLC: A trial of the ECOG-ACRIN Cancer Research Group (EA5181).

H. Wakelee, S. Ramalingam, C. Lovly, 2021 .

Phase I Study of Docetaxel and Concomitant Chest Radiation

E. Vokes, D. Haraf, G. Masters, 1997 .

American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer.

Thomas J. Smith, G. Giaccone, C. Azzoli, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2022.2

Gregory Riely, S. Temin, P. Ellis, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.2

Erin L. Schenk, Nofisat Ismaila, L. Sequist, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.2

Nofisat Ismaila, Gregory Riely, I. Jaiyesimi, 2023, Journal of Clinical Oncology.

Phase 3 comparison of high-dose once-daily (QD) thoracic radiotherapy (TRT) with standard twice-daily (BID) TRT in limited stage small cell lung cancer (LSCLC): CALGB 30610 (Alliance)/RTOG 0538.

J. Bradley, R. Komaki, L. Gaspar, 2021 .

Short Communication: Interim toxicity analysis for patients with limited stage small cell lung cancer (LSCLC) treated on CALGB 30610 (Alliance) / RTOG 0538.

L. Gaspar, E. Vokes, M. Dobelbower, 2021, Lung cancer.

Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer.

J. Hainsworth, J. Hamm, K. Albain, 2011, Lung cancer.

P-612 Gefitinib (Iressa, ZD1839) is active as first-line, compassionate use therapy in patients with advanced non-small cell lung cancer (NSCLC)

A. Argiris, G. Masters, N. Mittal, 2003 .

Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.

S. Jewell, C. Morrison, M. Edelman, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Therapy of advanced metastatic lung cancer with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience.

A. Bardia, R. Heist, W. Messersmith, 2015 .

Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly diagnosed, Ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Alliance A041703.

W. Stock, G. Uy, H. Erba, 2023, Journal of Clinical Oncology.

A Phase II Study of Induction Chemotherapy Followed by Thoracic Radiotherapy and Erlotinib in Poor-Risk Stage III Non–Small-Cell Lung Cancer: Results of CALGB 30605 (Alliance)/RTOG 0972 (NRG)

P. Jänne, J. Bradley, E. Vokes, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103.

C. Rudin, R. Salgia, E. Vokes, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Eicosanoid modulation in advanced non-small cell lung cancer (NSCLC): CALGB 30203.

M. Edelman, E. Vokes, R. Kratzke, 2006, Journal of Clinical Oncology.

Vinorelbine (Navelbine), cisplatin, and concomitant radiation therapy for advanced malignancies of the chest: a Phase I study.

E. Vokes, D. Haraf, G. Masters, 1996, Seminars in oncology.